FTN Equity Capital rated Buy Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) on 03/12/2009, when the stock price was $10.44. Since then, Biomarin Pharmaceutical Inc. has gained 1153.74% as of 11/25/2015's recent price of $130.89.
If you would have followed this FTN Equity Capital 's recommendation on BMRN, you would have gained 1153.73% of your investment in 2449 days.

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Having access to accurate and timely information is essential for success in today's marketplace. At FTN Equity Capital Markets, our focus is on providing thorough and objective research to our clients, empowering them to make the well-informed and educated decisions that help enhance their investment process. Our highly experienced team of analytical experts research, examine, and evaluate businesses in several markets, including consumer, health care, business and technology services, and financial service sectors.

Marked as spam